Baltimore, MD: MedTalk: Meet Michael Kauffman, M.D., Ph.D. ’92, CEO and Co-Founder, Karyopharm Therapeutics, Inc.
Join Andrea Cox, M.D.-Ph.D. ’98, Director M.D.-Ph.D. Program and Professor of Medicine and Michael Kauffman, M.D.-Ph.D. '92, CEO, Karyopharm Therapeutics, Inc. to learn about Dr. Kauffman’s non-traditional career path, his experiences as a student and what led him to entrepreneurial success. Karyopharm focuses on the discovery, development and commercialization of first-in-class agents targeting nuclear transport for the treatment of cancer and other major diseases such as myelodysplastic syndrome, colorectal and prostate cancer, advanced solid malignancies or non-Hodgkin’s lymphoma.
This is a terrific opportunity for current M.D.-Ph.D. and Ph.D. students to gain career insights, network and learn from Dr. Kauffman’s experiences. Refreshments, light lunch and networking will follow the discussion.
Students are encouraged to prepare questions in advance.
About Dr. Kauffman
Dr. Kauffman co-founded Karyopharm with Dr. Sharon Shacham in 2008 and has served as Chief Executive Officer since January 2011. Prior to joining Karyopharm, Dr. Kauffman served as Chief Medical Officer at Onyx Pharmaceuticals Inc. and as an operating partner at Bessemer Venture Partners where he led investments in biotechnology companies. In addition, he led the Velcade® (bortezomib) development program and the discovery and development of novel molecular diagnostics for major cancers including melanoma. He currently serves on the board of directors and compensation committee of Verastem Inc., a publicly-traded biopharmaceutical company. Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College, his Doctor of Medicine and Doctor of Philosophy from Johns Hopkins Medical School, and trained in internal medicine and rheumatology at Beth Israel (now Beth Israel Deaconess Medical Center) and Massachusetts General Hospitals. He is board certified in internal medicine. Karyopharm focuses on nuclear medicine for the treatment of cancer and is the industry leader in oral SINE technology https://www.karyopharm.com/about/management-team/